einstein (São Paulo). 17/Jan/2019;17(1):eAO3434.

Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer

Luana Carolina Ferreira Fiuza Silva ORCID logo , Lilian Silva Martins de Arruda ORCID logo , Waldec Jorge David Filho ORCID logo , Felipe José Silva Melo Cruz ORCID logo , Damila Cristina Trufelli ORCID logo , Auro del Giglio ORCID logo

DOI: 10.31744/einstein_journal/2019AO3434

ABSTRACT

Objective

To define a predictive factor for pathologic complete response, compare the oncologic outcomes associated with the degree of pathologic response after neoadjuvant chemotherapy, and to analyze pathologic complete response as a prognostic factor for overall survival and progression-free survival.

Methods

A retrospective study of patients admitted to Hospital Estadual Mário Covas and Hospital Anchieta from 2008 to 2012, with locally advanced breast cancer. Hormone receptor status, HER2 status, histologic and nuclear grade, age upon diagnosis and histological type of the tumor were analyzed. Pathologic evaluation of the tumor was subdivided into pathologic complete response, defined by the absence of tumor; intermediate response, considered as a favorable stage; and poor response, considering low-responder patients. Data obtained were submitted to statistical analysis.

Results

The study included 243 patients. There was an association of pathologic complete response with HER-2 negative, histological grade 3, stage III, hormone receptor negative, positive lymph node, older age and more advanced tumors. However, after multivariate analysis the only predictor of pathologic complete response was the presence of negative hormone receptor. By analyzing the prognostic factors, hormone receptor negative was considered as an independent risk factor, and pathologic complete response was considered as an independent protective factor.

Conclusion

Hormone receptor negative is predictive of pathologic complete response and is an isolated risk factor for lower progression-free survival and overall survival. Pathologic complete response is a protective factor for these same survival analyses.

Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer

Comments